BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29483217)

  • 1. The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic
    Forsythe N; Refaat A; Javadi A; Khawaja H; Weir JA; Emam H; Allen WL; Burkamp F; Popovici V; Jithesh PV; Isella C; Labonte MJ; Mills IG; Johnston PG; Van Schaeybroeck S
    Mol Cancer Ther; 2018 Jun; 17(6):1280-1290. PubMed ID: 29483217
    [No Abstract]   [Full Text] [Related]  

  • 2. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
    Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
    Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.
    Carson R; Celtikci B; Fenning C; Javadi A; Crawford N; Carbonell LP; Lawler M; Longley DB; Johnston PG; Van Schaeybroeck S
    Clin Cancer Res; 2015 Jul; 21(14):3230-3240. PubMed ID: 25813020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
    Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
    Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
    Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
    Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
    Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ
    Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
    Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with
    Yao YM; Donoho GP; Iversen PW; Zhang Y; Van Horn RD; Forest A; Novosiadly RD; Webster YW; Ebert P; Bray S; Ting JC; Aggarwal A; Henry JR; Tiu RV; Plowman GD; Peng SB
    Clin Cancer Res; 2017 Sep; 23(18):5547-5560. PubMed ID: 28611205
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase.
    Merlot AM; Shafie NH; Yu Y; Richardson V; Jansson PJ; Sahni S; Lane DJR; Kovacevic Z; Kalinowski DS; Richardson DR
    Biochem Pharmacol; 2016 Jun; 109():27-47. PubMed ID: 27059255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.
    Croft A; Tay KH; Boyd SC; Guo ST; Jiang CC; Lai F; Tseng HY; Jin L; Rizos H; Hersey P; Zhang XD
    J Invest Dermatol; 2014 Feb; 134(2):488-497. PubMed ID: 23921951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.
    Maione F; Oddo D; Galvagno F; Falcomatà C; Pandini M; Macagno M; Pessei V; Barault L; Gigliotti C; Mira A; Corti G; Lamba S; Riganti C; Castella B; Massaia M; Rad R; Saur D; Bardelli A; Di Nicolantonio F
    Mol Oncol; 2024 Jun; 18(6):1552-1570. PubMed ID: 38348572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
    Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J
    Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
    Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
    Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
    [No Abstract]   [Full Text] [Related]  

  • 16. A synthetic chalcone, 2'-hydroxy-2,3,5'-trimethoxychalcone triggers unfolded protein response-mediated apoptosis in breast cancer cells.
    Lee DH; Jung Jung Y; Koh D; Lim Y; Lee YH; Shin SY
    Cancer Lett; 2016 Mar; 372(1):1-9. PubMed ID: 26742460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic BRAF, endoplasmic reticulum stress, and autophagy: Crosstalk and therapeutic targets in cutaneous melanoma.
    Rather RA; Bhagat M; Singh SK
    Mutat Res Rev Mutat Res; 2020; 785():108321. PubMed ID: 32800272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of CEMIP suppresses proliferation and induces apoptosis in colorectal cancer cells: downregulation of GRP78 and attenuation of unfolded protein response.
    Liang G; Fang X; Yang Y; Song Y
    Biochem Cell Biol; 2018 Jun; 96(3):332-341. PubMed ID: 29024602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mitogen-activated protein kinase signaling pathway sensitizes breast cancer cells to endoplasmic reticulum stress-induced apoptosis.
    Yang F; Tang XY; Liu H; Jiang ZW
    Oncol Rep; 2016 Apr; 35(4):2113-20. PubMed ID: 26796921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
    Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
    Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.